Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 5/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.46 |
| ▸ | LMNA | P02545 | 5/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2659793 | 0.82 | CYP1A2 (0.51) | HSP90AA1ATMMAPTALDH1A1LMNA | |
| SCHEMBL7933915 | 0.82 | GPR35 (0.46) | HSP90AA1ATMMAPTGAAALDH1A1 | |
| SCHEMBL6448588 | 0.82 | ALDH1A1 (0.49) | MAPTALDH1A1KMT2ASMN1; SMN2MAPK1 | |
| SCHEMBL31285140 | 0.79 | TSHR (0.49) | MAPTALDH1A1LMNAKMT2AMEN1 | |
| SCHEMBL3156146 | 0.79 | LMNA (0.57) | HSP90AA1ATMMAPTGAAALDH1A1 | |
| SCHEMBL18146104 | 0.79 | ALDH1A1 (0.54) | HSP90AA1ATMMAPTGAAALDH1A1 | |
| SCHEMBL12306339 | 0.79 | MAPT (0.42) | HSP90AA1ATMMAPTALDH1A1KMT2A | |
| SCHEMBL6179703 | 0.79 | LMNA (0.51) | MAPTALDH1A1LMNAKMT2ASMN1; SMN2 | |
| SCHEMBL31261399 | 0.79 | ALDH1A1 (0.54) | HSP90AA1ATMMAPTGAAALDH1A1 | |
| SCHEMBL29718848 | 0.78 | CA2 (0.44) | MAPTALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050143384-A1 | Amide thiadiazole inhibitors of plasminogen activator inhibitor-1 | BRISTOL-MYERS SQUIBB COMPANY | 2005-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050143384-A1 | Amide thiadiazole inhibitors of plasminogen activator inhibitor-1 | SERPINE1, SERPINC1, SERPINB1 | HSD17B10 1589/4885HSP90AA1 1354/4885ATM 1322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.